The Viscous Dosing Syringe (VDS) platform reduces the manual force required to inject, thereby enabling users to more comfortably inject highly viscous drugs (up to 3000cP), as well as cold drugs and drugs requiring a fine injection needle.
It is easy to use and includes a proprietary integrated passive needle safety technology, making it suitable for use by a clinician, caregiver or patient (self-injection). This versatile platform incorporates standard pre-fillable syringes and has a wide array of customization options.
The VDS is suitable for applications where the injection force is high.
This is the case with viscous drugs, as viscosity has a direct impact on injection force, making it hard in some cases for users to manually depress the plunger rod.
Pharmaceutical formulations are increasingly becoming viscous due to trends towards more high strength biological therapeutics and/or long-acting formulations. Viscosity can range from 10-150cP concentrated biologic formulations found in oncology, autoimmune disorders, ophthalmology, and other areas, and several long-acting formulations have even higher viscosities (1000cP+).
Pharmaceutical companies often have to increase injection volume to offset effect of higher formulation viscosity, which leads them to require more than one injection device for a complete dose or use expensive larger volume injection platforms such as patch pumps or even consider IV therapy / infusions. The Congruence VDS is a suitable alternative to these expensive and/or less user-friendly options.
Other application areas can include drugs that are refrigerated, as at lower temperatures injectable therapies can become more viscous, raising the possibility of users experiencing high injection forces if the drug is injected too soon after refrigeration removal. Drugs that are delivered through a fine needle gauge will experience higher injection forces, so the VDS is also applicable there.
Congruence devices have been shown to inject high viscosity formulations with significantly low force from the user compared to a standard pre-fillable syringe [PFS] alone even when incorporating the same PFS.
The reduction in required user force results in much higher user acceptance in comparison to PFS. Indeed, 100% of the clinicians in a Congruence user study preferred the Congruence VDS device over only the PFS.
The VDS platform was featured in a presentation at PODD 2021.
Additional data available upon request